Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
V114 vaccine for prevention of acute otitis media in children
NCT04193215Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Sep 2020
- Primary completion
- Dec 2025
- Modality
- Split/Subunit Vaccines
- Countries
- 1
01
Overview
Phase 3, randomised trial of pneumococcal 15-valent conjugate vaccine in acute otitis media (AOM) (2 arms), sponsored by Merck & Co. Primary endpoints: Number of Participants with a First Episode of Vaccine-Type Acute Otitis Media at 36 months, Percentage of Participants with Serious Adverse Events at 36 months and 3 more. Started Sep 2020; status: completed.
02
Drugs
pneumococcal 15-valent conjugate vaccine
03
Conditions
acute otitis media (AOM)
Beyond the preview
Go deeper on NCT04193215.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04193215.